Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics. Cytosolix's Tumor Activated Permeability System, produces weakly-acidic derivatives of known oncology drugs, that enhance the uptake by cancer cells while restricting the uptake by healthy cells, enabling physicians to get safer and more effective therapy for drugs with dose-limiting toxicities.

Tolland, CT, USA

Cytosolix

Backed is a London-based VC fund, set up to do things differently.\r\n\r\nWe back unashamedly ambitious founders, building tech companies that give people greater freedom. \r\nWe invest at the seed stage in Europe and the US. \r\n\r\nWe’re a young team - our founders are our peers. \r\nWe roll up our sleeves - companies deserve more than just capital. \r\n\r\nOur platform helps founders hire talent, develop their brands, build communities and expand internationally.

Job Opportunities in the Backed Portfolio